Organometallics
Article
(6) Berners-Price, S. J.; Filipovska, A. Gold compounds as therapeutic
agents for human diseases. Metallomics 2011, No. 41, 279−304.
(7) Komeda, S.; Casini, A. Next-generation anticancer metallodrugs.
Curr. Top. Med. Chem. 2012, 12, 219−223.
(8) Bergamo, A.; Gaiddon, C.; Schellens, J. H. M.; Beijnen, J. H.;
Sava, G. Approaching tumour therapy beyond platinum drugs: status
of the art and perspectives of ruthenium drug candidates. J. Inorg.
Biochem. 2012, 106, 90−99.
(9) Harding, M. M.; Mokdsi, G. Antitumour metallocenes: structure-
activity studies and interactions with biomolecules. Curr. Med. Chem.
2000, 7, 1289 and references therein.
(26) Schuh, E.; Pfluger, C.; Citta, A.; Folda, A.; Rigobello, M. P.;
Bindoli, A.; Casini, A.; Mohr, F. Gold(I) carbene complexes causing
thioredoxin 1 and thioredoxin 2 oxidation as potential anticancer
agents. J. Med. Chem. 2012, 55, 5518−5528 and references therein.
(27) Berners-Price, S. J.; Filipovska, A. Gold compounds as
therapeutic agents for human diseases. Metallomics 2011, 3, 863−873.
(28) Dalla Via, L.; Nardon, C.; Fregona, D. Targeting the ubiquitin-
proteasome pathway with inorganic compounds to fight cancer: a
challenge for the future. Future Med. Chem. 2012, 4, 525−543.
(29) Casini, A.; Kelter, G.; Gabbiani, C.; Cinellu, M. A.; Minghetti,
G.; Fregona, D.; Fiebig, H.-H.; Messori, L. Chemistry, antiproliferative
properties, tumor selectivity, and molecular mechanisms of novel
gold(III) compounds for cancer treatment: a systematic study. J. Biol.
Inorg. Chem. 2009, 14, 1139−1149.
(10) Kopf-Maier, P.; Kopf, H. Titanocene dichloride - the first
̈
̈
metallocene with cancerostatic activity. Angew. Chem., Int. Ed. Engl.
1979, 18, 477.
(30) Magherini, F.; Modesti, A.; Bini, L.; Puglia, M.; Landini, I.;
Nobili, S.; Mini, E.; Cinellu, M. A.; Gabbiani, C.; Messori, L. Exploring
the biochemical mechanisms of cytotoxic gold compounds: a
proteomic study. J. Biol. Inorg. Chem. 2010, 15, 573−582.
(31) Zhu, Y.; Cameron, B. R.; Mosi, R.; Anastassov, V.; Cox, J.; Qin,
L.; Santucci, Z.; Metz, M.; Skerlj, R. T.; Fricker, S. P. Inhibition of the
cathepsin cysteine proteases B and K by square-planar cycloaurated
gold(III) compounds and investigation of their anti-cancer activity. J.
Inorg. Biochem. 2011, 105, 754−762.
(32) Erdogan, E.; Lamark, T.; Stallings-mann, M.; Jamieson, L.;
Pellecchia, M.; Thompson, E. A.; Johansen, T.; Fields, A. P.
Aurothiomalate inhibits transformed growth by targeting the PB1
domain of protein kinase Cι. J. Biol. Chem. 2006, 281, 28450−28459.
(33) Stallings-Mann, M.; Jamieson, L.; Regala, R. P.; Weems, C.;
Murray, N. R.; Fileds, A. P. A novel small molecule inhibitor of protein
kinase Cι blocks transformed growth of non-small-cell lung cancer cell.
Cancer Res. 2006, 66, 1767−1764.
(34) Jeon, K. I.; Biun, M. S.; Jue, D. M. Gold compound auranofin
inhibits IκB kinase (IKK) by modifying Cys-179 of IKKβ subunit. Exp.
Mol. Med. 2003, 35, 61−66.
(35) Serratrice, M.; Edafe, F.; Mendes, F.; Scopelliti, R.; Zakeeruddin,
S. M.; Gratzel, M.; Santos, I.; Cinellu, M. A.; Casini, A. Cytotoxic gold
compounds: synthesis, biological characterization and investigation on
their inhibition properties of the zinc finger protein PARP-1. Dalton
Trans. 2012, 41, 3287−3293.
(11) Berdel, W. E.; Schmoll, H. J.; Scheulen, M. E.; Korfel, A.;
Knoche, M. F.; Harstrick, A.; Bach, F.; Sa, G. Phase I clinical trial of
titanocene dichloride in adults with advanced solid tumors. J. Cancer
Res. Clin. Oncol. 1994, 120 (Suppl), R172.
(12) Abeysinghe, P. M.; Harding, M. M. Antitumor bis-
(cyclopentadienyl) metal complexes: titanocene and molybdocene
dichloride and derivatives. Dalton Trans. 2007, 3474 and references
therein.
(13) Olszewski, U.; Hamilton, G. Mechanisms of cytotoxicity of
anticancer titanocenes. Anti-Cancer Agents Med. Chem. 2010, 10, 320
and references therein.
(14) Lummen, G.; Sperling, H.; Lubolt, H.; Otto, T.; Rubben, H.
Phase II trial of titanocene dichloride in advanced renal-cell carcinoma.
Cancer Chemother. Pharmacol. 1998, 42, 415.
(15) Kroger, N.; Kleeberg, U. R.; Mross, K.; Edler, L.; Sab, G.;
Hossfeld, D. Phase II clinical trial of titanocene dichloride in patients
with metastatic breast cancer. Onkologie 2000, 23, 288.
(16) Strohfeldt, K.; Tacke, M. Biorganometallic fulvene-derived
titanocene anti-cancer drugs. Chem. Soc. Rev. 2008, 37, 1174−1187.
(17) Recent selected example: Olszewski, U.; Deally, A.; Tacke, M.;
Hamilton, G. Alterations of phosphoproteins in NCI-H526 small cell
lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y.
Neoplasia 2012, 14, 813−822 and references therein.
́
(18) Beckhove, P.; Oberschmidt, O.; Hanauske, A. R.; Pampillon, C.;
Schirrmacher, V.; Sweeney, N. J.; Strohfeldt, K.; Tacke, M. Antitumor
activity of titanocene Y against freshly explanted human breast tumor
cells and in xenografted MCF-7 tumors in mice. Anti-Cancer Drugs.
2007, 18, 311.
(36) Mendes, F.; Groessl, M.; Nazarov, A. A.; Tsybin, Y. O.; Sava, G.;
Santos, I.; Dyson, P. J.; Casini, A. Metal-based inhibition of
poly(ADPribose)polymerase−the guardian angel of DNA. J. Med.
Chem. 2011, 54, 2196−2206.
́
(19) Bannon, J. H.; Fitchner, I.; O’Neill, A.; Pampillon, C.; Sweeney,
(37) Lease, N.; Vasileviski, V.; Carreira, M.; de Almeida, A.; Sanau,
́
N. J.; Strohfeldt, K.; Watson, R. W.; Tacke, M.; Mc Gee, M. M.
Substituted titanocenes induce caspase-dependent apoptosis in human
epidermoid carcinoma cells in vitro and exhibit antitumor activity in
vivo. Br. J. Cancer. 2007, 97, 1234.
M.; Hirva, P.; Casini, A.; Contel, M. Potential anticancer
heterometallic Fe−Au and Fe−Pd agents: initial mechanistic insights.
J. Med. Chem. 2013, 56, 5806−5818.
(38) Cooper, B. G.; Napoline, J. W.; Thomas, C. Catalytic
applications of early/late heterobimetallics. Catal. Rev: Sci. Eng.
2012, 54, 1−40.
́
(20) Fichtner, I.; Pampillon, C.; Sweeney, N. J.; Strohfeldt, K.; Tacke,
M. Anti-tumor activity of titanocene Y in xenografted Caki-1 tumors in
mice. Anti-Cancer Drugs 2006, 17, 333.
(21) Fichtner, I.; Behrens, D.; Claffey, J.; Deally, A.; Gleeson, B.;
Patil, S.; Weber, H.; Tacke, M. The antiangiogenic and antitumoral
activity of Titanocene Y* in vivo. Lett. Drug Des. Discovery 2011, 8,
302−307.
(22) Walther, W.; Fichtner, I.; Deally, A.; Hogan, M.; Tacke, M. The
activity of Titanocene T against xenografted caki-1 tumors. Lett. Drug
Des. Discovery 2013, 10, 375−381.
(23) Bertrand, B.; Casini, A. A golden future in medicinal inorganic
chemistry: the promise of anticancer organometallic gold complexes.
Dalton Trans. 2014, 43, 4209−4219.
(24) Nobili, S.; Mini, E.; Landini, I.; Gabbiani, C.; Casini, A.;
Messori, L. Gold compounds as anticancer agents: chemistry, celular
pharmacology, and preclinical studies. Med. Res. Rev. 2010, 30, 550−
580.
(25) Casini, A.; Hartinger, C.; Gabbiani, C.; Mini, E.; Dyson, P. J.;
Keppler, B. K.; Messori, L. Gold(III) compounds as anticancer agents:
relevance of gold-protein interactions for their mechanism of action. J.
Inorg. Biochem. 2008, 102, 564−575.
(39) Pelletier, F.; Comte, V.; Massard, A.; Wenzel, M.; Toulot, S.;
Richard, P.; Picquet, M.; Le Gendre, P.; Zava, O.; Edafe, F.; Casini, A.;
Dyson, P. J. Development of bimetallic titanocene-ruthenium-arene
complexes as anticancer agents: relationships between structural and
biological properties. J. Med. Chem. 2010, 53, 6923−6933.
(40) Wenzel, M.; Bertrand, B.; Eymin, M.-J.; Comte, V.; Harvey, J.
A.; Richard, P.; Groessl, M.; Zava, O.; Amrouche, H.; Harvey, P. D.; Le
Gendre, P.; Picquet, M.; Casini, A. Multinuclear cytotoxic metal-
lodrugs: physicochemical characterization and biological properties of
novel heteronuclear gold-titanium complexes. Inorg. Chem. 2011, 50,
9472−9480.
́
(41) Gonzalez-Pantoja, J. F.; Stern, M.; Jarzecki, A. A.; Royo, E.;
Robles-Escajeda, E.; Varela-Ramirez, A.; Aguilera, R. J.; Contel, M.
Titanocene-phosphine derivatives as precursors to cytotoxic hetero-
metallic TiAu2 and TiM (M = Pd, Pt) compounds. studies of their
interactions with DNA. Inorg. Chem. 2011, 50, 11099−11110.
(42) (a) Chen, X.; Zhou, L. The hydrolysis chemistry of anticancer
drug titanocene dichloride: an insight from theoretical study. J. Mol.
Struct. 2010, 940, 45−49. (b) Olszewski, U.; Hamilton, G.
6680
dx.doi.org/10.1021/om500965k | Organometallics 2014, 33, 6669−6681